$HIMS

HIMS

Hims & Hers Health, Inc. Class A Common Stock

本窗口内的全部观点与内容

截至 09-26
09-25
09-18
Schwab Network发布 2026-09-18
《40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"》
$HIMS看涨
HIMS 估值偏低、具备上行潜力;其平台模式可从任何胜出的 GLP-1 药物中获取价值,随着市值增长,做空压力将逐步减弱。

我想谈谈“Hems & Hers Health”这家公司。这是另一个备受关注的名称,尤其是在社交媒体上。它是一只波动较大的股票,但似乎正处于过渡阶段,我很想知道你对它在这个领域所扮演角色的看法,以及你对这家公司的总体看法。

I want to talk about the company "Hems & Hers Health". This is another name that is attracting a lot of attention, especially on social media. It's a volatile stock, but it seems to be in a transitional phase, and I'm interested to know your opinion on its role in this area, and your general opinion of the company .

09-16
Parkev Tatevosian, CFA发布 2026-09-16
《Is Hims & Hers Stock a Buy Right Now in September? | HIMS Stock Analysis》
$HIMS看涨
对于风险承受能力较高的长期投资者而言,HIMS 因增长前景强劲且估值合理而值得买入。

Hims & Hers 管理层向投资者重申了其长期业绩指引。管理层预计,到2030年营收至少达到65亿美元,调整后息税折旧摊销前利润达到13亿美元。

Hims & Hers management team reiterated its longer-term guidance to investors. The management team is forecasting at least $6.5 billion in revenue by 2030 and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization.

但这是否意味着 Hims & Hers 的股票对长期投资者来说是一个买入机会?因此,到2030年营收至少达到60亿美元,将是其最近12个月营收总额的两倍多。在这一时期,Hims & Hers 报告的营收为26亿美元。

这较2020年的约2.5亿美元有所增长。这一直是全球增长最快的公司之一。

But does this make Hims & Hers stock a buying opportunity for long-term investors? So, revenue of at least $6 billion by 2030 would be more than double their most recent trailing 12-month total.

In that period, Hims & Hers reported $2.6 billion in revenue. That's up from around $250 million in 2020. This has been one of the fastest-growing companies in the world.

他说在等
调整后EBITDA到2030年超过10亿美元
若实现,将改善盈利能力和利润率
到2030年未来财务报告
支持关于盈利能力改善的看多论点
09-01
《The Hims & Hers Australia Strategy: Why It Matters for Investors》
$HIMS看涨
HIMS是一个高增长的非对称投资案例;若成为全球医疗需求聚合者,其价值可能增长10至100倍。

作为美国领先的远程医疗公司,对 Hims & Hers 来说可能是一个 10 倍的机会,甚至更大,但成为全球远程医疗公司——无论你身在何处,都能回答你所有问题的地方——才是医疗保健和 Hims & Hers 真正巨大的机会所在。

Being a leading telehealth company in the US could be a 10x, maybe even a bigger opportunity for Hims & Hers, but beating being the global telehealth company where you go to answer all your questions no matter where you are in the world is really where the massive opportunity is for healthcare and for Hims & Hers.

更早的记录
已显示 4 / 本页 4 条
看这只股票的全部记录